Purple Biotech (NASDAQ:PPBT) Shares Cross Above 50 Day Moving Average – Time to Sell?

Shares of Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $1.41 and traded as high as $1.49. Purple Biotech shares last traded at $1.49, with a volume of 20,258 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Purple Biotech from a “sell (e+)” rating to a “sell (e)” rating in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $30.00.

Purple Biotech Price Performance

The stock has a market cap of $1.38 million, a PE ratio of -0.06 and a beta of 0.77. The business has a 50 day moving average price of $1.41 and a two-hundred day moving average price of $2.84.

About Purple Biotech

Purple Biotech Ltd. (NASDAQ:PPBT) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research programs are designed to address mechanisms that contribute to tumor growth, immune evasion and resistance to existing treatments. Purple Biotech’s pipeline has included CM24, a humanized monoclonal antibody targeting CEACAM1, an immune checkpoint involved in tumor-immune interactions. The company has evaluated CM24 in combination with other cancer therapies, including immune checkpoint inhibitors, for advanced solid tumors such as metastatic pancreatic cancer.